ABSTRACT
Background Pakistan has a hepatitis C virus (HCV) infection prevalence of 6–9% and aims to achieve World Health Organization (WHO) targets for elimination of HCV by the year 2030 through scaling HCV diagnosis and accelerating access to care. The clinical and economic benefits of various HCV testing strategies have not yet been evaluated in Pakistan.
Objective To evaluate the potential cost-effectiveness of a reference laboratory-based (CEN) confirmatory testing approach vs a molecular near-patient point-of-care (POC) confirmatory approach to screen the general population for HCV in Pakistan.
Methods We developed a decision-analytic model comparing HCV testing under two scenarios: screening with an anti-HCV antibody test (Anti-HCV) followed by either POC nucleic acid testing (NAT) (Anti-HCV-POC), or reference laboratory NAT (Anti-HCV-CEN), using data from published literature, the Pakistan Ministry of Health, and expert judgment. Outcome measures included: number of HCV infections identified per year, percentage of individuals correctly classified, total costs, average costs per individual tested, and cost-effectiveness. Sensitivity analysis was also performed.
Results At a national level for a tested population of 25 million, the Anti-HCV-CEN strategy would identify 142,406 more HCV infections in one year and increase correct classification of individuals by 0.57% compared with the Anti-HCV-POC strategy. The total annual cost of HCV testing was reduced using the Anti-HCV-CEN strategy by $7.68 million ($0.31 per person). Thus, incrementally, the Anti-HCV-CEN strategy costs less and identifies more HCV infections than Anti-HCV-POC.
Conclusions Anti-HCV-CEN would provide the best value for money when scaling up HCV testing in Pakistan.
Significance statement
Hepatitis C virus (HCV) infection constitutes a major medical and public health burden in Pakistan
Widespread testing is important to identify those that are chronically infected in order to link them to treatment services
The optimal and most cost-effective testing approach to scale up HCV testing to support elimination efforts in Pakistan has not been established
High throughput reference laboratory testing would provide the best value for money when scaling-up HCV testing in Pakistan
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: JBB and SC served as paid consultants to Roche Molecular Systems, Inc. JKK is an employee of Roche Diagnostics Solutions. MBM is an employee of Roche Molecular Systems, Inc. MMC was an employee of Roche Molecular Systems, Inc. at the time this study was conducted and remains a stockholder. LPG served as a paid consultant to Roche Molecular Systems, Inc. and received grants or has contracts with Gilead Sciences. SSH has no conflicts of interest to declare. COBAS is a trademark of Roche. All other product names and trademarks are the property of their respective owners.
Funding Statement
This study was funded by Roche Molecular Systems, Inc. Editorial support with the preparation of the manuscript was provided by Tina Patrick at Elements Communications Ltd., Westerham, UK and was funded by Roche Molecular Systems, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patient-related data were obtained from published literature. Citations to literature included in the analysis are provided within the manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- Ab
- antibody
- CHEERS
- Consolidated Health Economic Evaluation Reporting Standards
- CEN
- central laboratory testing
- CI
- confidence interval
- DAA
- direct-acting antiviral agent
- DBS
- dried blood spot
- EC
- electric consumption
- FN,
- false negative
- FP
- false positive
- HCV
- hepatitis C virus
- HIV
- human immunodeficiency virus
- ICER
- incremental cost-effectiveness ratio
- kWa
- kilowatt hour
- LMIC
- low- and middle-income country
- LTFU
- lost to follow-up
- MOH
- Ministry of Health
- NAT
- nucleic acid test
- P
- probability
- POC
- point of care
- PSA
- probabilistic sensitivity analysis
- PSC
- Plasma Separation Card
- RDS
- Roche Diagnostic Systems
- RNA
- ribonucleic acid
- TN
- true negative
- TP
- true positive
- US
- United States
- VA
- volt-ampere
- WHO
- World Health Organization
